Latest Industry Insights

In this interview, Erik Digman Wiklund tells us about the discovery of circRNA and discusses some of the challenges of harnessing its full potential for therapeutic interventions.

At the European Laboratory Research and Innovation Group’s (ELRIG) Research and Innovation 2024 event, we asked a selection of start-up companies in the biotech space the same question: what are the key challenges you currently face?

We spoke with Dr. Bryan Oronsky, chief development officer at EpicentRx, to discover more about the promise of multipurpose drugs and the potential of EpicentRx’s nibrozetone (RRx-001) for several conditions.

The industry's search for alternatives to traditional preclinical drug testing methods has led to a growing interest in the potential of three-dimensional (3D) in vitro models. To delve deeper into this subject, Technology Networks spoke with Madhu Lal-Nag, chief scientific officer at InSphero, a 3D in vitro model company with a mission to “modernize drug discovery in ways that inspire researchers everywhere to reach their full potential and fuel a new era of breakthrough therapies.”

Technology Networks recently connected with Vincent Pluvinage, CEO of OneD Battery Sciences, and George Schlowsky, president of Koch Modular, to shed light on the advancements of anode technology within the EV battery industry.

Scott Ripley explores how realizing the potential of mRNA therapeutics will require the standardization of processes, manufacturing agility and collaboration between industry, academia and government bodies.

John Puglia outlines and compares the capabilities offered by single-use technologies and stainless steel systems, with a focus on the flexibility of implementing SUTs.

In this interview, Dr. Mason tells us about her career path and experiences along the way, as well as sharing advice for women considering a career in science.

In this opinion piece, Amy Butler shares her career path from lab to leadership, including how she was able to rise up in the ranks despite being an introvert.

We spoke to Olivier Barberan, director of Translational Medicine Solutions at Elsevier, to find out more about how predictive tools can inform pharma companies and help pave the way for drugs to get to market.